<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762866</url>
  </required_header>
  <id_info>
    <org_study_id>080606</org_study_id>
    <nct_id>NCT00762866</nct_id>
  </id_info>
  <brief_title>Psychiatric Genotype/Phenotype Project Repository</brief_title>
  <acronym>PGPP</acronym>
  <official_title>Psychiatric Genotype/Phenotype Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to obtain DNA, brain imaging data, other biological samples&#xD;
      (e.g., urine, serum), and a comprehensive clinical assessment on patients with schizophrenia&#xD;
      and other psychotic disorders, bipolar disorder, major depression, and normal volunteer&#xD;
      controls. Understanding the physical and genetic factors related to these disorders will help&#xD;
      us make progress in fitting treatments to an individual's needs. Participants will take part&#xD;
      in a detailed clinical assessment, two blood draws, and an MRI scan over two visits.&#xD;
      Participants will also be asked to provide urine and saliva samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The links between psychiatric symptoms and underlying biological processes remain unclear at&#xD;
      this time. Unipolar Major Depressive Disorder, Bipolar Disorder, and Schizophrenia are&#xD;
      associated with major disruptions in functioning and quality of life. Understanding the&#xD;
      causal physiological and genetic factors involved in each of these disorders would allow us&#xD;
      to make great strides in tailoring treatment to the individual's needs. Because the etiology&#xD;
      of these disorders are likely multifactorial in nature, a study examining a wide range of&#xD;
      variables might best allow us to examine the interactions between different factors and to&#xD;
      get a better sense of how genes and the brain interact to produce psychiatric disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>Brain volume</measure>
    <time_frame>2 years</time_frame>
    <description>Observational neuromaging study</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>Unipolar Major Depressive Disorder, any subtype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar</arm_group_label>
    <description>Bipolar I or II Disorder or Bipolar Disorder NOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychosis</arm_group_label>
    <description>Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient Mental Health Clinic, Inpatient Psychiatric Hospital, Research Volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 16 and 65&#xD;
&#xD;
          2. Able and willing to provide informed consent&#xD;
&#xD;
          3. Able to read and speak English sufficiently to provide consent and answer questions&#xD;
&#xD;
          4. Diagnosis of one of the following:&#xD;
&#xD;
               -  Unipolar Major Depressive Disorder of any subtype&#xD;
&#xD;
               -  Bipolar I, Bipolar II Disorder, or Bipolar Disorder NOS&#xD;
&#xD;
               -  Axis I Psychotic Disorder, which can include the diagnoses of Schizophrenia,&#xD;
                  Schizoaffective Disorder, Major Depression or Mania with Psychotic Features,&#xD;
                  Schizophreniform Disorder, Brief Psychotic Episode, or Psychotic Disorder NOS&#xD;
&#xD;
               -  Normal volunteer controls, individuals with no personal history of any Axis I&#xD;
                  disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reported pregnancy or breastfeeding&#xD;
&#xD;
          2. Dementia or delirium&#xD;
&#xD;
          3. Any medical condition that would interfere with participation in the study. This would&#xD;
             include, but not be limited to:&#xD;
&#xD;
               -  uncontrolled diabetes, hypothyroidism, Cushing's disease, or other significant&#xD;
                  endocrine condition (treated endocrine condition is allowed)&#xD;
&#xD;
               -  demyelinating disease&#xD;
&#xD;
               -  HIV infection&#xD;
&#xD;
               -  active hepatitis&#xD;
&#xD;
               -  CNS infection&#xD;
&#xD;
               -  clinically significant and unstable cardiovascular disease&#xD;
&#xD;
               -  any cancer involving the CNS (including metastatic disease)&#xD;
&#xD;
          4. Exclusion criteria for normal control subjects include any history of mental illness&#xD;
             or psychotropic drug abuse.&#xD;
&#xD;
          5. Participants will be excluded from the imaging portion of the study if they have any&#xD;
             condition deemed to interfere with PET or MRI scanning, such as but not restricted to&#xD;
             extreme obesity, metal fragments in eyes, metal implants in the head, or cochlear&#xD;
             implant. These participants may still take part in the portion of the study involving&#xD;
             the clinical assessment and providing biological samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Heckers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephan Heckers</investigator_full_name>
    <investigator_title>Chair of the Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Bipolar II Disorder</keyword>
  <keyword>Bipolar Disorder NOS</keyword>
  <keyword>Psychotic Disorder</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

